Study wrapper · #1050
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Wei Y, Gong Y, Gong J, et al. Journal of obstetrics and gynaecology. 2026.
DOI: 10.1080/01443615.2026.2701996PubMed: 42495930
Editor's note
A small (n=53) non-randomized observational comparison, so the findings are hypothesis-generating rather than definitive. Semaglutide was associated with one-year weight loss but higher two-year weight regain (55.6%) than the structured lifestyle arm. Group sizes were uneven and outcomes were not adjusted for confounders, so read the comparative results with caution.
Plain-language abstract
This small prospective observational study compared semaglutide, sleeve gastrectomy, and a structured lifestyle programme for weight control in 53 endometrial cancer patients pursuing fertility-sparing care. Semaglutide produced weight loss at one year but was associated with more weight regain by two years than the lifestyle programme.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026